Y-mAbs Therapeutics, Inc. (YMAB)

Y-mAbs Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. The company has a license and research collaboration agreement with Memorial Sloan Kettering Cancer Center. Y-mAbs Therapeutics, Inc. was founded in 2015 and is headquartered in New York, New York.

Current Quote*
Last: $32.970
Change: -0.320
Book: $13.140
Volume: 181,623

As Of: 12/06 17:36 ET
*Quotes delayed by 20min.

Graphs for YMAB


3 Month Graph


6 Month Graph


1 Year Graph